Background: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Aim: To report incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the tofacitinib UC programme. Methods: DVT and PE were evaluated from one phase 2 and two phase 3 induction studies, one phase 3 maintenance study and an ongoing, open-label, long-term extension (OLE) study (September 2018 datacut). Data were analysed in induction, maintenance and overall (patients receiving ≥ 1 dose of tofacitinib 5 or 10 mg b.d. in any phase 2, 3 or OLE study) cohorts. Results: 1157 patients (2404 patient-years' exposure; ≤ 6.1 years' tofacitinib treatment) were evaluated in the overall cohort. In induction, one placebo-treated patient had DVT and one had PE; no tofacitinib-treated patients had DVT/PE. In maintenance, one placebo-treated patient had DVT and one had PE; no tofacitinib-treated patients had DVT/PE. In the overall cohort, one patient had DVT (incidence rate [patients with events/100 patient-years; 95% CI]: 0.04 [0.00-0.23]); four had PE (0.16 [0.04-0.41]); all received predominant dose tofacitinib 10 mg b.d.; all had venous thromboembolism risk factors alongside UC. Conclusions: In this post hoc analysis of patients with UC, during tofacitinib exposure, one patient had DVT and four had PE, all during the OLE study, on predominant dose 10 mg b.d. (83% of overall cohort patients received predominant dose 10 mg b.d.) with venous thromboembolism risk factors. This analysis is limited by small sample size and limited drug exposure; further studies are needed. ClinicalTrials.gov: NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612.
| INTRODUC TI ON
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Tofacitinib safety in UC was evaluated in phase 2 and phase 3 randomised controlled studies, 1, 2 and in an ongoing, open-label, long-term extension (OLE) study. 3 Recently, the data safety monitoring board for tofacitinib rheumatology studies determined that the frequency of pulmonary embolism (PE) in the tofacitinib 10 mg twice daily (b.d.) arm was higher than the frequency of PE in the tumour necrosis factor inhibitor comparator arm in an FDA post-marketing requirement safety study (A3921133; NCT02092467) 4 designed to evaluate the long-term risk of major adverse cardiovascular events and malignancy.
Study A3921133 is an ongoing, open-label, endpoint-driven study, evaluating the safety of tofacitinib 5 mg b.d. and tofacitinib 10 mg b.d. compared with tumour necrosis factor inhibitors in patients with rheumatoid arthritis. Patients had to be 50 years of age or older, had at least one cardiovascular risk factor and be on a stable dose of methotrexate to be eligible for enrolment.
Subsequently, based on the information from study A3921133 and consideration of information pertaining to PE for other Janus kinase inhibitors, Pfizer has determined as part of its pharmacovigilance procedures that PE is an important potential risk for treatment with tofacitinib.
The non-A3921133 rheumatoid arthritis studies included placebo-controlled (≤ 3 months of follow-up), active-controlled (up to 24 months of follow-up) and OLE (up to 9.5 years of tofacitinib treatment follow-up) periods. 5, 6 Data from these phase 2, phase 3 and OLE studies of tofacitinib in rheumatoid arthritis (excluding study A3921133) showed that incidence rates (IRs; patients with events per 100 patient-years) for deep vein thrombosis (DVT) and PE in the placebo group during the placebo-controlled period were 0.41 [95% confidence interval (CI): 0.01-2.30] for DVT and 0.41 [0.01-2.30] for PE. The IRs in tofacitinib-treated patients (5 mg b.d. and 10 mg b.d. doses) from all periods were in the range of 0.00-0.21 for DVT and 0.00-0.15 for PE, and were similar with tofacitinib 5 mg b.d. and 10 mg b.d. doses. 5 7, 8 Reported literature values for IRs of thromboembolic events among persons with rheumatoid arthritis treated with a variety of biologic and/or conventional therapies ranged between 0.04-0.79. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Rheumatoid arthritis is a known risk factor for DVT/PE events, with a risk ratio for DVT of 2.08 and a risk ratio for PE of 2.17 for rheumatoid arthritis vs nonrheumatoid arthritis, based on a metaanalysis of nine observational studies in patients with rheumatoid arthritis. 23 UC is a known risk factor for DVT/PE events, with reported IRs of 0.07-0.30 for DVT and 0.04-0.20 for PE. [24] [25] [26] We report incidence of venous thromboembolic events in the tofacitinib UC clinical development programme as of September 2018.
| MATERIAL S AND ME THODS
We evaluated DVT and PE events in the tofacitinib UC clinical development programme in three cohorts. The induction cohort included patients receiving placebo or tofacitinib 10 mg b.d. in phase 2 (A3921063) or phase 3 induction studies (OCTAVE Induction 1 and 2). The maintenance cohort included patients receiving placebo, database not locked). Study designs were described previously. [1] [2] [3] 27 DVT and PE events were identified using clinically relevant pre- [2] ; one patient died due to one of the events assessed as severe). Each of the events in the overall tofacitinib-treated cohort occurred during the OLE study; all patients were from the predominant dose tofacitinib 10 mg b.d. group. Demographics and clinical characteristics for patients with DVT/PE events are presented in Table 2 . Further details for each of the patients with DVT/PE events are provided below.
| RE SULTS
In the induction studies, DVT/PE events occurred in two placebo-treated patients: DVT, a n (%) (1); the second assessed as mild (1). e Severities were assessed as moderate (2) and severe (2). 24, 26 The present post hoc analysis provides information for physicians regarding the incidence of DVT and PE in patients with UC who were treated with tofacitinib, but is limited by small sample size and drug exposure. Further studies of venous thromboembolism in patients with UC treated with tofacitinib are needed. Additional analyses are ongoing to further characterise the association between treatment with tofacitinib and PE in other populations, including patients with rheumatoid arthritis. Given that PE has been determined as an important potential risk of treatment with tofacitinib, prescribers should review information pertaining to PE and tofacitinib in their current local product labelling (eg USPI in the US 28 and SmPC in the EU 29 ) and individualise treatment by considering risk factors for venous thromboembolism.
| DATA S HARING S TATEMENT
Upon request, and subject to certain criteria, conditions and exceptions (see https ://www.pfizer.com/scien ce/clini cal-trial s/trialdata-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (a) for indications that have been approved in the US and/or EU or (b) in programmes that have been terminated (ie development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.
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